Bitopertin’s Schizophrenia Failure Stirs Doubt About Roche’s CNS Plans

Roche’s bitopertin fails in the first two of six Phase III schizophrenia trials to report, raising questions about prospects for more diversity outside the company’s core strength in oncology.